Novo CEO eyes cheap biotech market: "Of course the price matters, but there are other factors, too"
Big biotech price drops could create acquisition opportunities similar to the firm’s record-breaking purchase of Dicerna, says Novo Nordisk CEO Lars Fruergaard Jørgensen, explaining that the company is looking at a wide range of disease areas for potential purchases.
by ANDREAS LØNSTRUP, translated by daniel pedersen & catherine brett
Novo Nordisk expects future research and development expenditures will increase at a higher rate than the company’s top line growth. This will ensure that one or more successors are ready once the pharmaceutical firm’s current growth engine, semaglutide, loses its patent.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
